Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234580 | 1.00 | PRMT1 (0.47) | PRMT1ATMADRA1ACA1CA2 | |
| SCHEMBL585705 | 0.94 | PRMT1 (0.55) | PRMT1ADRA1ALMNAEPHX2TSHR | |
| SCHEMBL8944734 | 0.92 | PRMT1 (0.59) | PRMT1ADRA1APLA2G4ALMNAEPHX2 | |
| SCHEMBL17234155 | 0.87 | ECE1 (0.43) | PRMT1ADRA1ACA1CA2LMNA | |
| SCHEMBL10752337 | 0.87 | ECE1 (0.43) | PRMT1ADRA1ACA1CA2LMNA | |
| SCHEMBL28236290 | 0.83 | PRMT1 (0.47) | PRMT1ATMADRA1ACA1CA2 | |
| SCHEMBL19933297 | 0.82 | ADRA1A (0.47) | PRMT1ATMADRA1ACA1CA2 | |
| SCHEMBL25366603 | 0.80 | PRMT1 (0.44) | PRMT1ATMADRA1ACA1CA2 | |
| SCHEMBL2035521 | 0.78 | PRMT1 (0.54) | PRMT1ATMADRA1ACA1CA2 | |
| SCHEMBL33717 | 0.74 | PRMT1 (0.50) | PRMT1ATMADRA1APLA2G4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012247-A1 | SHORT PEPTIDES WHICH SELECTIVELY MODULATE INTRACELLULAR SIGNALLING | The Children's Medical Center Corporation (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1998053051-A1 | SHORT PEPTIDES WHICH SELECTIVELY MODULATE INTRACELLULAR SIGNALLING | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-11-26 | — | — | WO | claimed |
| US-12378301-B2 | B1SP fusion protein therapeutics, methods, and uses | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-08-05 | — | — | US | disclosed |
| CN-112533938-B | Polypeptides self-assembled into nanoparticles | 苏黎世联邦理工学院 | 2025-04-25 | — | — | CN | disclosed |
| CN-119546765-A | Hybrid oligonucleotides | 恩特拉达治疗学股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119390777-A | Zwitterionic fluorescent probe containing dimeric targeting ligand and preparation method and application thereof | 北京声光纳医疗科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119156395-A | Cyclic peptides for delivery of therapeutic agents | 恩特拉达治疗学股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118284434-A | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118215504-A | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20080182258-A1 | Q3 SPARC DELETION MUTANT AND USES THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-7332568-B2 | Q3 SPARC deletion mutant and uses thereof | ABRAXIS BIOSCIENCE, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080038280-A1 | A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines | GOVERNMENT OF THE UNITED STATES OF AMERICA (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2008017734-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008000079-A1 | SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) AS CHEMOTHERAPEUTIC SENSITIZERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-01-03 | — | — | WO | disclosed |
| EP-1869077-A2 | Q3 SPARC DELETION MUTANT AND USES THEREOF | Abraxis BioScience, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070212363-A1 | Immunoglobulins with Potent and Broad Antiviral Activity | THE GOV OF USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2006112930-A2 | Q3 SPARC DELETION MUTANT AND USES THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060199248-A1 | Q3 SPARC deletion mutant and uses thereof | AMERICAN BIOSCIENCE, INC. (US) | 2006-09-07 | — | — | US | disclosed |